BioPharmSignal logoBioPharmSignal

Biotech News

Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares

Genenta Science (GNTA)Genenta ScienceFinancing

MILAN and NEW YORK , Oct. 27, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that it has entered into a securities purchase agreement with institutional investors to purchase 4,285,715 American Depositary Shares ("ADSs") at an offering price

Related news

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

ZNTLZentalis2026-08-14 02:23 EST

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

ERASErasca2026-07-14 03:10 EST

Erasca Announces Pricing of Upsized Public Offering of Common Stock

ERASErasca2026-07-13 20:19 EST

Erasca Announces Proposed Public Offering of $500 Million of Common Stock

ELVNEnliven Therapeutics2026-06-12 02:39 EST

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

IDYAIDEAYA Biosciences2026-06-10 20:05 EST

IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

LEGNLegend Biotech Corporation2026-06-18 01:21 EST

Legend Biotech Corporation Announces Pricing of Public Offering

GNTAGenenta Science2026-07-22 08:00 EST

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

View all latest news

Genenta Science

Genenta Science is a cell-therapy company focused on engineered myeloid cells and cancer immunotherapy. Its platform aims to create a new class of cellular medicine for oncology.

Recent company news

GNTAGenenta Science2026-07-23 07:09 EST

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

GNTAGenenta Science2026-07-22 08:00 EST

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

GNTAGenenta Science2026-04-23 11:00 EST

Genenta signs Definitive Agreements with Sophia High Tech

GNTAGenenta Science2026-03-27 09:00 EST

Genenta, evolving into Saentra Forge, has signed a Binding Offer with Sòphia High Tech, an Italian company manufacturing critical parts for Europe's space and defense programs

GNTAGenenta Science2026-03-24 07:26 EST

Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini

Stock data

Close
1.26 USD
Market cap
51.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States